Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Sep;63(5):811-828.
doi: 10.1016/j.resinv.2025.06.014. Epub 2025 Jul 3.

The JRS guideline for the management of pneumonia in adults 2024

Affiliations
Free article
Practice Guideline

The JRS guideline for the management of pneumonia in adults 2024

Hiroshi Mukae et al. Respir Investig. 2025 Sep.
Free article

Abstract

The Japanese Respiratory Society published the Adult Pneumonia Practice Guidelines 2024 in April 2024. In Japan, a super-aged society, the disease burden of pneumonia is significant and is expected to grow in the future. Given this historical context, the most important themes in this revision of the guidelines include the appropriate use of antibiotics and measures against pneumonia in older adults. A large portion of these cases involves aspiration pneumonia, making it challenging to achieve fundamental improvement with antibiotic treatment alone and necessitating a comprehensive approach. Preventing pneumonia and maintaining physical function are essential points for improving the prognosis of pneumonia in older adults, with an emphasis on promoting vaccination, rehabilitation, and oral care. The treatment of Nursing and Healthcare-Associated Pneumonia (NHCAP), a Japan-specific category adapted from the ATS/IDSA's HCAP guidelines, has been extensively reviewed. Despite international moves away from HCAP due to concerns about the overuse of broad-spectrum antibiotics, Japan has chosen to retain NHCAP for treating pneumonia in older adults while implementing stricter controls on antibiotic use to promote antimicrobial stewardship. In cases of repeated aspiration pneumonia or in situations where the patient is in a terminal state of age-related decline or the final stage of comorbidities, all pneumonia patients are recommended to undergo a background assessment, occasionally prioritizing palliative care and respecting the patient's outlook on life. The importance of advanced care planning has also been highlighted to underscore the need for interdisciplinary collaboration with medical doctors and other healthcare professionals.

Keywords: Antibiotic stewardship; Interdisciplinary collaboration; Japanese guidelines; Pneumonia in adults.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Hiroshi Mukae received honoraria from Shionogi & Co., Ltd., KYOLIN Pharmaceutical Co., Ltd., Pfizer Japan Inc., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Insmed Incorporated, Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Gilead Sciences Inc., Asahi Kasei Pharma Corporation, AstraZeneca K.K., GlaxoSmithKline K.K., and Taisho Pharma Co., Ltd., a research grant from Nippon Boehringer Ingelheim Co., Ltd., Taiho Pharmaceutical Co., Ltd., Taisho Pharma Co., Ltd., Ltd., KYORIN Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. and subsidies or donations from Taiho Pharmaceutical Co., Ltd. and Taisho Pharma Co., Ltd.; Dr. Katsunori Yanagihara received honoraria from KYORIN Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., GlaxoSmithKline K.K., Becton, Dickinson and Company, Shionogi & Co., Ltd., BioMérieux Japan Ltd., a research grant from Fujifilm Toyama Chemical Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and subsidies or donations from KYORIN Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.; Dr. Kazuhiro Yatera received honoraria from GlaxoSmithKline K.K., AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., a research grant from Insmed Inc., Bayer Pharma Japan, KYORIN Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., and subsidies or donations from Taiho Pharmaceutical Co., Ltd., Teijin Home Healthcare Ltd., and Teijin Pharma Ltd.; Dr. Kosaku Komiya received honoraria from KYORIN Pharmaceutical Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.; Dr. Makoto Miki received honoraria from KYOLIN Pharmaceutical Co., Ltd.; Dr. Naoki Iwanaga received a research grant from MSD K.K. and Fujifilm Toyama Chemical Co., Ltd.; Dr. Naoyuki Miyashita received honoraria from AstraZeneca K.K., KYORIN Pharmaceutical Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Taisho Pharma Co., and Astellas Pharma Inc.; Dr. Nobuaki Shime received honoraria from Beckton Dickinson Japan, and Asahi-kasei Pharma.; Dr. Shinji Teramoto received honoraria from AstraZeneca K.K., KYORIN Pharmaceutical Co., Ltd., Novartis Pharma K.K., and Nippon Boehringer Ingelheim Co., Ltd.; Dr. Tetsuya Matsumoto received honoraria from KYORIN Pharmaceutical Co., Ltd., MSD K.K., and Pfizer Japan Inc.; Dr. Yuichiro Shindo received honoraria from KYORIN Pharmaceutical Co., Ltd., AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Gilead Sciences Inc., MSD K.K., GlaxoSmithKline plc., Insmed, Inc., Asahi Kasei Pharma Co., Ltd., and Pfizer Inc., and a research grant from Japan Society for the Promotion of Science. He participated on a Data Safety Monitoring Board or Advisory Board of GlaxoSmithKline BIOLOGICALS SA, Insmed, Inc., and Pfizer Inc.; Drs. Futoshi Higa, Hiroki Tsukada, Hiroshi Takahashi, Kazuyoshi Senda, Masahiro Yoshida, Nobuyuki Horita, Takaya Maruyama, Yoshifumi Imamura, and Yoshihiro Yamamoto have no conflict of interest.

Publication types

Substances

LinkOut - more resources